Wenhao Hu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wenhao Hu has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Bing Wu
Department of Urology, State Key Laboratory of Virology and Biosafety, Medical Research Institute, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan 430071, China
2 shared publications Jie Sun
Department of Urology, State Key Laboratory of Virology and Biosafety, Medical Research Institute, Zhongnan Hospital of Wuhan University, Wuhan University
2 shared publicationsShumin Wang
Biotherapy Center and Cancer Center, The First Affiliated Hospital of Zhengzhou University , Zhengzhou, Henan
2 shared publications- Yi Zhang
Biotherapy Center and Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
2 shared publications Yue Liang
Department of Biochemistry and Molecular Biology, Tongji Medical College, Huazhong University of Science and Technology
2 shared publications- Bin Zhang
Department of Hematology and Oncology, Northwestern University, Chicago, United States of America
1 shared publication
Latest Publications
- Open Access
- 29 April 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (18)
Cytochrome P450 1B1 directs pathogenic Th17 cell generation and autoimmune disease by fine-tuning redox homeostasis and mitochondrial integrity
Th17 cell function is highly context-dependent and can be categorized into pathogenic and nonpathogenic Th17 cell subsets. Understanding the molecule control of pathogenic Th17 (pTh17) cell immunity will benefit the treatment for related autoimmune diseases. Here, we revealed that cytochrome P450 1B1 (CYP1B1) is highly upregulated during mice and human colitis. CYP1B1 promoted both colon inflammatory diseases and colitis-associated colorectal cancer via pTh17-dependent but microbiota-independent manner. Notably, CYP1B1 specifically dictated the differentiation and pathogenicity of pTh17 cells, while having no effects on nonpathogenic Th17 cell generation. Mechanistically, CYP1B1 deficiency disrupted intracellular redox homeostasis via decreased glutathione synthetase, leading to increased ROS and mitochondrial dysfunction of pTh17 cells. ROS elimination by N-acetylcysteine or ectopic glutathione synthetase expression restored mitochondrial fitness and promoted pTh17 cell survival and generation. Taken together, our findings uncover a T cell intrinsic CYP1B1–ROS–mitochondrial axis in driving pTh17 cell generation, interfering with this hub may be beneficial for pTh17 cell-related immunopathology.
- 29 April 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (18)
Open AccessCytochrome P450 1B1 directs pathogenic Th17 cell generation and autoimmune disease by fine-tuning redox homeostasis and mitochondrial integrity
Th17 cell function is highly context-dependent and can be categorized into pathogenic and nonpathogenic Th17 cell subsets. Understanding the molecule control of pathogenic Th17 (pTh17) cell immunity will benefit the treatment for related autoimmune diseases. Here, we revealed that cytochrome P450 1B1 (CYP1B1) is highly upregulated during mice and human colitis. CYP1B1 promoted both colon inflammatory diseases and colitis-associated colorectal cancer via pTh17-dependent but microbiota-independent manner. Notably, CYP1B1 specifically dictated the differentiation and pathogenicity of pTh17 cells, while having no effects on nonpathogenic Th17 cell generation. Mechanistically, CYP1B1 deficiency disrupted intracellular redox homeostasis via decreased glutathione synthetase, leading to increased ROS and mitochondrial dysfunction of pTh17 cells. ROS elimination by N-acetylcysteine or ectopic glutathione synthetase expression restored mitochondrial fitness and promoted pTh17 cell survival and generation. Taken together, our findings uncover a T cell intrinsic CYP1B1–ROS–mitochondrial axis in driving pTh17 cell generation, interfering with this hub may be beneficial for pTh17 cell-related immunopathology.
- Open Access
- 23 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1)
Fructose intake driven glycolysis-ROS-EGFR axis specifically promotes the generation and pathogenicity of Th17 cells
Th17 cells are quite heterogeneous. Treating Th17-related inflammatory disorders requires understanding the functionally diverse subtypes in the context of tissue homeostasis, which is shaped by nutrient availability among other factors. Here, we show that increased consumption of fructose exacerbates colitis and experimental autoimmune encephalomyelitis (EAE), via pathogenic Th17 cells. Fructose selectively enhances the differentiation and function of this pathogenic subtype of Th17 cells, which are induced by a combination of IL1β, IL-6 and IL-23 (pTh17). In contrast, TGFβ1and IL-6-induced homeostatic, non-pathogenic Th17 cells remain unaffected. Notably, fructose enhances metabolic activity in pTh17 cells, leading to increased ROS production and subsequently promoting pathogenic-Th17 cell differentiation. N-acetyl cysteine (NAC), a ROS scavenger, specifically impaired pathogenic-Th17 cell immunity and mitigated high-fructose regulated colitis and EAE disease. Mechanistically, ROS accumulation results in elevated EGFR expression and phosphorylation, which leads to increased nuclear translocation. Nuclear EGFR binds to STAT3, enhancing its transcriptional activity at the CNS6 and CNS9 regions of Rorc. In summary, our work describes here a mechanism through which high fructose intake specifically exacerbates pathogenic Th17-cell-related pathologies and provides potential therapeutic targets for pTh17-mediated diseases.
- 23 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1)
Open AccessFructose intake driven glycolysis-ROS-EGFR axis specifically promotes the generation and pathogenicity of Th17 cells
Th17 cells are quite heterogeneous. Treating Th17-related inflammatory disorders requires understanding the functionally diverse subtypes in the context of tissue homeostasis, which is shaped by nutrient availability among other factors. Here, we show that increased consumption of fructose exacerbates colitis and experimental autoimmune encephalomyelitis (EAE), via pathogenic Th17 cells. Fructose selectively enhances the differentiation and function of this pathogenic subtype of Th17 cells, which are induced by a combination of IL1β, IL-6 and IL-23 (pTh17). In contrast, TGFβ1and IL-6-induced homeostatic, non-pathogenic Th17 cells remain unaffected. Notably, fructose enhances metabolic activity in pTh17 cells, leading to increased ROS production and subsequently promoting pathogenic-Th17 cell differentiation. N-acetyl cysteine (NAC), a ROS scavenger, specifically impaired pathogenic-Th17 cell immunity and mitigated high-fructose regulated colitis and EAE disease. Mechanistically, ROS accumulation results in elevated EGFR expression and phosphorylation, which leads to increased nuclear translocation. Nuclear EGFR binds to STAT3, enhancing its transcriptional activity at the CNS6 and CNS9 regions of Rorc. In summary, our work describes here a mechanism through which high fructose intake specifically exacerbates pathogenic Th17-cell-related pathologies and provides potential therapeutic targets for pTh17-mediated diseases.
- 28 June 2025
- Published by Oxford University Press (OUP) in The Journal of Immunology
HMGB1 inhibits the IFN-γ–induced PD-L1 expression in NSCLC
T cells are the most important cytotoxic cells involved in antitumor immune responses. After recognizing the major histocompatibility complex (MHC)–peptide complex, cytokines including interferon-γ (IFN-γ) are released to kill tumor cells. However, IFN-γ can also induce tumor cells to express PD-L1. This molecule can bind to PD-1 on the surface of T cells to exert inhibitory functions. In response to stimuli, like chemoradiotherapy or immunotherapy, tumor cells release damage-associated molecular patterns, including high-mobility group protein B1 (HMGB1). Our previous studies revealed that HMGB1 can increase the antitumor activity of T cells and enhance the secretion of cytokines, including IFN-γ. However, the effect of HMGB1 on PD-L1 expression in non-small cell lung cancer remains unclear. Here, we examined the expression of HMGB1 and PD-L1 in tumor tissue slices of patients with non-small cell lung cancer with high expression of IFN-γ and observed that they exhibited a negative correlation, which was also verified by our analysis in The Cancer Genome Atlas. In vitro experiments demonstrated that HMGB1 could bind to RAGE (receptor for advanced glycation end products) and inhibit IFN-γ induction of PD-L1 by inhibiting the JAK1/STAT3 pathway. In vitro and in vivo experiments indicated that HMGB1 enhanced the antitumor effects of chimeric antigen receptor T cells and inhibited tumor growth. These results showed that HMGB1 inhibited IFN-γ–induced PD-L1 expression, thereby enhancing the antitumor effects of T cells, and confirmed the role of HMGB1 as a prognostic indicator for lung cancer treated with chimeric antigen receptor T cells.
- 28 June 2025
- Published by Oxford University Press (OUP) in The Journal of Immunology
HMGB1 inhibits the IFN-γ–induced PD-L1 expression in NSCLC
T cells are the most important cytotoxic cells involved in antitumor immune responses. After recognizing the major histocompatibility complex (MHC)–peptide complex, cytokines including interferon-γ (IFN-γ) are released to kill tumor cells. However, IFN-γ can also induce tumor cells to express PD-L1. This molecule can bind to PD-1 on the surface of T cells to exert inhibitory functions. In response to stimuli, like chemoradiotherapy or immunotherapy, tumor cells release damage-associated molecular patterns, including high-mobility group protein B1 (HMGB1). Our previous studies revealed that HMGB1 can increase the antitumor activity of T cells and enhance the secretion of cytokines, including IFN-γ. However, the effect of HMGB1 on PD-L1 expression in non-small cell lung cancer remains unclear. Here, we examined the expression of HMGB1 and PD-L1 in tumor tissue slices of patients with non-small cell lung cancer with high expression of IFN-γ and observed that they exhibited a negative correlation, which was also verified by our analysis in The Cancer Genome Atlas. In vitro experiments demonstrated that HMGB1 could bind to RAGE (receptor for advanced glycation end products) and inhibit IFN-γ induction of PD-L1 by inhibiting the JAK1/STAT3 pathway. In vitro and in vivo experiments indicated that HMGB1 enhanced the antitumor effects of chimeric antigen receptor T cells and inhibited tumor growth. These results showed that HMGB1 inhibited IFN-γ–induced PD-L1 expression, thereby enhancing the antitumor effects of T cells, and confirmed the role of HMGB1 as a prognostic indicator for lung cancer treated with chimeric antigen receptor T cells.
- Open Access
- 16 January 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (1) , e010540
Glut3 overexpression improves environmental glucose uptake and antitumor efficacy of CAR-T cells in solid tumors
Background Glucose deprivation inhibits T-cell metabolism and function. Glucose levels are low in the tumor microenvironment of solid tumors and insufficient glucose uptake limits the antitumor response of T cells. Furthermore, glucose restriction can contribute to the failure of chimeric antigen receptor T (CAR-T) cell therapy for solid tumors. However, the impact of glucose restriction remains unknown in CAR-T cell therapy. Methods Glucose transporters were detected and overexpressed in CAR-T cells. The impacts of glucose restriction on CAR-T cells were checked in vitro and in vivo. Results Glucose restriction significantly decreased CAR-T cell activation, effector function, and expansion. CAR-T cells expressed high levels of the glucose transporter Glut1, which has a low affinity for glucose. Overexpression of Glut1 failed to improve CAR-T cell function under glucose-restricted conditions. In contrast, the function and antitumor potential of CAR-T cells was enhanced by the overexpression of Glut3, which has the highest affinity for glucose among the Glut transporter family and is expressed in minor parts of CAR-T cells. Glut3-overexpressing CAR-T cells demonstrated increased tumoricidal efficacy in multiple xenografts and syngenetic mouse models. Furthermore, Glut3 overexpression activated the PI3K/Akt pathway and increased OXPHOS and mitochondrial fitness. Conclusions We provide a direct and effective approach to enhance low glucose uptake levels by CAR-T cells and improve their antitumor efficacy against solid tumors.
- 16 January 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (1) , e010540
Open AccessGlut3 overexpression improves environmental glucose uptake and antitumor efficacy of CAR-T cells in solid tumors
Background Glucose deprivation inhibits T-cell metabolism and function. Glucose levels are low in the tumor microenvironment of solid tumors and insufficient glucose uptake limits the antitumor response of T cells. Furthermore, glucose restriction can contribute to the failure of chimeric antigen receptor T (CAR-T) cell therapy for solid tumors. However, the impact of glucose restriction remains unknown in CAR-T cell therapy. Methods Glucose transporters were detected and overexpressed in CAR-T cells. The impacts of glucose restriction on CAR-T cells were checked in vitro and in vivo. Results Glucose restriction significantly decreased CAR-T cell activation, effector function, and expansion. CAR-T cells expressed high levels of the glucose transporter Glut1, which has a low affinity for glucose. Overexpression of Glut1 failed to improve CAR-T cell function under glucose-restricted conditions. In contrast, the function and antitumor potential of CAR-T cells was enhanced by the overexpression of Glut3, which has the highest affinity for glucose among the Glut transporter family and is expressed in minor parts of CAR-T cells. Glut3-overexpressing CAR-T cells demonstrated increased tumoricidal efficacy in multiple xenografts and syngenetic mouse models. Furthermore, Glut3 overexpression activated the PI3K/Akt pathway and increased OXPHOS and mitochondrial fitness. Conclusions We provide a direct and effective approach to enhance low glucose uptake levels by CAR-T cells and improve their antitumor efficacy against solid tumors.